Table 5 Biological determinants for clinical worsening and overall survival

From: Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

  Clinical worsening Overall survival
   Univariable analysis Multivariable analysis   Univariable analysis Multivariable analysis
  Frequency (%) nevents/npatients HR (95% CI) P value (Wald) HR (95% CI) P value (Wald) nevents/npatients HR (95% CI) P value (Wald) HR (95% CI) P value (Wald)
CRP 152    <0.0001   0.012    0.002   0.048
≤50 mg l−1 84 (55%) 12/84 1   1   7/84 1   1  
>50 mg l−1 68 (45%) 33/68 4.17 (2.15–8.09)   2.62 (1.24–5.56)   22/68 3.82 (1.63–8.94)   2.80 (1.01–7.78)  
Procalcitonin 143    <0.0001      <0.0001   
≤0.50 µg l−1 110 (77%) 21/110 1     10/110 1    
>0.5 µg l−1 33 (23%) 23/33 5.71 (3.15–10.35)     18/33 7.06 (3.26–15.3)    
Hemoglobin 157    0.003      0.06   
<10 g dl−1 47 (30%) 22/47 2.43 (1.35–4.36)     14/47 2.02 (0.97–4.19)    
≥10 g dl−1 110 (70%) 23/110 1     15/110 1    
Leukocytes 157    0.09      0.57   
<4,000 46 (29%) 11/46 0.97 (0.47–2.0)     8/46 1.12 (0.47–2.68)    
4–10,000 87 (56%) 22/87 1     14/87 1    
>10,000 24 (15%) 12/24 2.07 (1.02–4.18)     7/24 1.63 (0.66–4.04)    
Lymphocytes 155    0.009      0.026   
≤500 34 (22%) 16/34 2.28 (1.23–4.23)     11/34 2.38 (1.11–5.08)    
>500 121 (78%) 28/121 1     17/121 1    
Neutrophil/lymphocyte ratio 155    0.011      0.15   
<7 103 (67%) 21/103 1     14/103 1    
≥7 52 (33%) 23/52 2.16 (1.19–3.92)     14/52 1.72 (0.82–3.63)    
Monocytes 155    0.0003   0.30    0.0007   0.34
≤200 24 (15%) 13/24 3.42 (1.77–6.59)   1.50 (0.70–3.21)   10/24 3.83 (1.77–8.31)   1.58 (0.62–4.07)  
>200 131 (85%) 31/131 1   1   18/131 1   1  
Fibrinogen 151    0.007      0.10   
≤5 g l−1 83 (55%) 17/83 1     11/83 1    
>5 g l−1 68 (45%) 28/68 2.29 (1.25–4.18)     18/68 1.88 (0.89–3.99)    
Ferritin 129    0.002      0.0002   
≤1,000 ng ml−1 90 (69.8%) 20/90 1     8/90 1    
>1,000 ng ml−1 39 (30.2%) 20/39 2.66 (1.43–4.94)     16/39 5.10 (2.18–12.0)    
D-dimer 117    0.15   0.43    0.025   0.02
≤3 µg l−1 87 (74%) 27/87 1   1   14/87 1 - 1  
>3 µg l−1 30 (26%) 14/30 1.60 (0.84–3.05)   1.31 (0.67–2.52)   11/30 2.47 (1.12–5.46)   2.63 (1.15–6.01)  
LDH 151    <0.0001   0.0285    0.009   0.61
≤250 IU l−1 78 (52%) 10/78 1   1   7/78 1 - 1  
>250 IU l−1 73 (48%) 33/73 4.64 (2.28–9.45)   2.31 (1.09–4.88)   20/73 3.17 (1.34–7.51)   1.27 (0.51–3.16)  
Albumin 150    <0.0001      0.002   
≤30 g l−1 36 (24%) 21/36 3.73 (2.05–6.79)     14/36 3.35 (1.57–7.12)    
>30 g l−1 114 (76%) 22/114 1     13/114 1    
Troponin 112    0.0001      0.01   
≤ULN 84 (75%) 19/84 1     11/84 1    
>ULN 28 (25%) 18/28 3.59 (1.88–6.88)     12/28 2.96 (1.29–6.79)    
  1. The sample size varied between 157 and 112 patients, depending on the availability of samples for each laboratory test. The hazard ratio corresponds to the effect size of the covariable studied on the risk of clinical worsening or death. Statistical significance was determined by Cox models using the Wald test. Due to the exploratory nature of the analyses, no formal adjustment for multiplicity was done. All tests were two sided and significance was accepted at the 5% level.